[1] Reau NS, Lammert CS, Weinberg EM. Autoimmune hepatitis: Current and future therapies. Hepatol Commun, 2024, 8(6):e0458. [2] Shiffman ML. Autoimmune hepatitis: Epidemiology, subtypes, and presentation. Clin Liver Dis, 2024, 28(1):1-14. [3] Mercado LA, Gil-Lopez F, Chirila RM, et al. Autoimmune hepatitis: A diagnostic and therapeutic overview. Diagnostics (Basel), 2024, 14(4):382. [4] Durazzo M, Lupi G, Scandella M, et al. Autoimmune hepatitis treatment in the elderly: A systematic review. World J Gastroenterol, 2019, 25(22):2809-2818. [5] Sonthalia N, Jain S, Thanage R, et al. Clinical, serological, histopathological and treatment profile of autoimmune hepatitis in the elderly. Clin Exp Hepatol, 2020, 6(1):13-19. [6] Wei Q, Li W, He S, et al. An exploratory machine learning model for predicting advanced liver fibrosis in autoimmune hepatitis patients: A preliminary study. Ann Hepatol, 2025, 30(1):101754. [7] Suzuki H, Amano K, Yamaguchi K, et al. Histological improvement of hepatic fibrosis of decompensated liver cirrhosis after prednisolone and azathioprine treatment in a patient with autoimmune hepatitis. Kurume Med J, 2025, 71(1.2):69-74. [8] Czaja AJ. Cellular senescence and its pathogenic and therapeutic implications in autoimmune hepatitis. Expert Rev Gastroenterol Hepatol, 2024, 18(11):725-743. [9] 王绮夏, 蒋翔, 连敏, 等. 2015年欧洲肝病学会临床实践指南:自身免疫性肝炎. 临床肝胆病杂志, 2015, 31(12):2000-2019. [10] 张洪文, 刘会敏, 林睿, 等. 自身免疫性肝炎完全应答不良患者的临床特点分析. 中华肝脏病杂志, 2017, 25(10):755-759. [11] European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol, 2019, 70(1):172-193. [12] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci, 2001, 56(3):M146-M156. [13] Engel B, Diestelhorst J, Hupa-Breier KL, et al. Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis. Hepatol Int, 2024, 18(4):1214-1226. [14] Zanussi JT, Zhao J, Wei WQ, et al. Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease. BMC Rheumatol, 2023, 7(1):24. [15] Ungabissoon U, Hunnicutt J, McDermott EJ, et al. Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study. BMJ Open Gastroenterol, 2025, 12(1):e001809. [16] Kilani Y, Aldiabat M, Sirilan KYT, et al. The impact of metabolic dysfunction-associated steatotic liver disease on autoimmune hepatitis outcomes: A nationwide analysis of 2,880 records. Clin Transl Gastroenterol, 2025, 16(11):e00912. [17] Lim J, Kim YJ, et al. Impact of metabolic dysfunction-associated steatotic liver disease on hepatocellular carcinoma risk in autoimmune hepatitis. PLoS One, 2025, 20(7):e0325066. [18] Di Zeo-Sánchez DE, Díaz-Alberola I, Pinazo-Bandera JM, et al. Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD). Br J Pharmacol, 2025, 182(21):5303-5316. [19] Pasta A, Pieri G, Plaz Torres MC, et al. Characteristics and outcomes of hepatocellular carcinoma in patients with autoimmune hepatitis. Dig Dis Sci, 2025, 70(8):2865-2872. [20] Medina-Morales E, Ismail M, Goyal RM, et al. Waitlist and transplant outcomes in patients with metabolic dysfunction-associated steatotic liver disease and autoimmune hepatitis. Liver Int, 2024, 44(11):3083-3095. |